Core Viewpoint - Canopy Growth Corporation reported a quarterly loss of $0.14 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.15, and an improvement from a loss of $0.37 per share a year ago, indicating a positive earnings surprise of +6.67% [1] Financial Performance - The company posted revenues of $52.13 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 8.81%, and showing an increase from $48.39 million in the same quarter last year [2] - Over the last four quarters, Canopy Growth has surpassed consensus EPS estimates only once [2] Stock Performance - Canopy Growth shares have declined approximately 61.7% since the beginning of the year, contrasting with the S&P 500's gain of 7.8% [3] Future Outlook - The company's earnings outlook will be crucial for assessing future stock performance, including current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the next quarter is -$0.14 on revenues of $48.3 million, and for the current fiscal year, it is -$0.46 on revenues of $198.45 million [7] Industry Context - The Medical - Products industry, to which Canopy Growth belongs, is currently ranked in the bottom 39% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

分组1 - Stem, Inc. reported a quarterly loss of $3.73 per share, which was worse than the Zacks Consensus Estimate of a loss of $3, representing an earnings surprise of -24.33% [1] - The company posted revenues of $38.37 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 15.93%, and showing an increase from $34 million in the same quarter last year [2] - Over the last four quarters, Stem has surpassed consensus EPS estimates two times and topped revenue estimates three times [2] 分组2 - The stock has underperformed the market, losing about 3.4% since the beginning of the year, while the S&P 500 gained 7.9% [3] - The current consensus EPS estimate for the coming quarter is -$2.00 on revenues of $36.3 million, and for the current fiscal year, it is -$10.20 on revenues of $145.2 million [7] - The Computers - IT Services industry, to which Stem belongs, is currently in the bottom 40% of the Zacks industry rankings, indicating potential challenges ahead [8]

Group 1: Earnings Performance - Globalstar reported quarterly earnings of $0.13 per share, exceeding the Zacks Consensus Estimate of a loss of $0.09 per share, and improved from a loss of $0.15 per share a year ago, representing an earnings surprise of +244.44% [1] - The company posted revenues of $67.15 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 7.15% and increasing from $60.38 million year-over-year [2] Group 2: Stock Performance and Outlook - Globalstar shares have declined approximately 15.7% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $68.23 million, and for the current fiscal year, it is -$0.35 on revenues of $261.71 million [7] Group 3: Industry Context - The Satellite and Communication industry, to which Globalstar belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Group 1 - Relay Therapeutics reported a quarterly loss of $0.41 per share, better than the Zacks Consensus Estimate of a loss of $0.49, and an improvement from a loss of $0.69 per share a year ago, resulting in an earnings surprise of +16.33% [1] - The company achieved revenues of $0.68 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 35.40%, compared to zero revenues a year ago [2] - Relay Therapeutics shares have declined approximately 14.3% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] Group 2 - The earnings outlook for Relay Therapeutics is mixed, with the current consensus EPS estimate for the coming quarter at -$0.45 on $0.5 million in revenues, and -$1.86 on $19.09 million in revenues for the current fiscal year [7] - The Zacks Industry Rank indicates that the Medical - Drugs sector is currently in the top 35% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]

Financial Performance - Goodyear reported a quarterly loss of $0.17 per share, missing the Zacks Consensus Estimate of $0.37, and compared to earnings of $0.19 per share a year ago, representing an earnings surprise of -145.95% [1] - The company posted revenues of $4.47 billion for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.83%, and down from $4.57 billion year-over-year [2] - Over the last four quarters, Goodyear has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Stock Performance and Outlook - Goodyear shares have increased approximately 10.4% since the beginning of the year, outperforming the S&P 500's gain of 7.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $0.50 on revenues of $4.82 billion, and for the current fiscal year, it is $1.31 on revenues of $18.57 billion [7] Industry Context - The Rubber - Tires industry, to which Goodyear belongs, is currently ranked in the bottom 6% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Goodyear's stock performance [5] - The unfavorable trend in estimate revisions prior to the earnings release has resulted in a Zacks Rank 5 (Strong Sell) for Goodyear, suggesting expected underperformance in the near future [6]

Company Performance - Owlet, Inc. reported a quarterly loss of $0.05 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.21, representing an earnings surprise of +76.19% [1] - The company posted revenues of $26.1 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 19.51% and up from $20.7 million a year ago [2] - Over the last four quarters, Owlet has surpassed consensus EPS estimates three times and topped revenue estimates two times [2] Stock Movement and Outlook - Owlet shares have increased approximately 59.6% since the beginning of the year, outperforming the S&P 500's gain of 7.9% [3] - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.24 on revenues of $23.45 million, and for the current fiscal year, it is -$1.03 on revenues of $93.02 million [7] Industry Context - The Technology Services industry, to which Owlet belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Owlet's performance [5][6]

分组1 - TripAdvisor reported quarterly earnings of $0.46 per share, exceeding the Zacks Consensus Estimate of $0.42 per share, and up from $0.39 per share a year ago, representing an earnings surprise of +9.52% [1] - The company posted revenues of $529 million for the quarter ended June 2025, which was slightly below the Zacks Consensus Estimate by 0.27%, but an increase from $497 million year-over-year [2] - TripAdvisor has surpassed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has gained approximately 11.6% since the beginning of the year, outperforming the S&P 500's gain of 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is $0.62 on revenues of $572.28 million, and for the current fiscal year, it is $1.45 on revenues of $1.94 billion [7] - The Zacks Industry Rank indicates that the Internet - Commerce sector is currently in the bottom 34% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Core Insights - Sutro Biopharma, Inc. reported a quarterly loss of $0.14 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.39, and an improvement from a loss of $0.59 per share a year ago, resulting in an earnings surprise of +64.10% [1] - The company achieved revenues of $63.75 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 293.54%, compared to $25.71 million in the same quarter last year [2] - Sutro Biopharma's stock has declined approximately 55.6% year-to-date, contrasting with the S&P 500's gain of 7.9% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.24 on revenues of $14.66 million, and for the current fiscal year, it is -$1.79 on revenues of $62.76 million [7] Industry Context - Sutro Biopharma operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable industry outlook [8] - The performance of Sutro Biopharma's stock may be influenced by the overall industry trends, as historically, the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8] Estimate Revisions - The trend of estimate revisions for Sutro Biopharma was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - Amphastar Pharmaceuticals reported quarterly earnings of $0.85 per share, exceeding the Zacks Consensus Estimate of $0.71 per share, but down from $0.94 per share a year ago, indicating an earnings surprise of +19.72% [1][2] Financial Performance - The company posted revenues of $174.41 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.69%, but down from $182.39 million year-over-year [2] - Over the last four quarters, Amphastar has surpassed consensus EPS estimates two times and topped consensus revenue estimates once [2] Stock Performance - Amphastar shares have declined approximately 43.9% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] Future Outlook - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at $0.83 for the coming quarter and $3.17 for the current fiscal year [7] - The Zacks Rank for Amphastar is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Industry Context - The Medical - Generic Drugs industry, to which Amphastar belongs, is currently in the bottom 34% of over 250 Zacks industries, suggesting potential challenges ahead [8]

分组1 - SolarEdge Technologies reported a quarterly loss of $0.81 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.82, and an improvement from a loss of $1.79 per share a year ago, indicating an earnings surprise of +1.22% [1] - The company posted revenues of $289.43 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.74% and showing an increase from year-ago revenues of $265.4 million [2] - SolarEdge shares have increased approximately 89.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.69 on revenues of $302.07 million, and for the current fiscal year, it is -$3.29 on revenues of $1.1 billion [7] - The Zacks Industry Rank indicates that the solar industry is currently in the bottom 39% of over 250 Zacks industries, which may impact stock performance [8] - Sunnova Energy, another company in the solar industry, is expected to report a quarterly loss of $0.71 per share, with revenues projected to be $266 million, reflecting a year-over-year increase of 21.1% [9]